GeoVax Labs, Inc.

GeoVax Labs, Inc. (GOVX) is a publicly listed company on US equity markets.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

The company reports net loss of $5.26M.

Key metrics include a return on equity of -1065.7%, a debt-to-equity ratio of 5.04.

Use FINOTAUR to track GOVX's price action, review fundamentals, and stay current with company news — all in one research dashboard.